Basic Information
| LncRNA/CircRNA Name | CEBPA-AS1 |
| Synonyms | NA |
| Region | GRCh38_19:33302857-33305054 |
| Ensemble | ENSG00000267296 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | liver cancer |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, in vitro knockdown, RNAi |
| Sample | HepG2 liver cancer cells, Liver cancer tissues and corresponding adjacent tissues |
| Expression Pattern | up-regulated |
| Function Description | The expression of lncRNA CEBPA-AS1 increased significantly in liver cancer tissues (p<0.05). Meanwhile, CEBPA-AS1 expression was associated with tumor size, portal vein tumor thrombus and invasion and metastasis (p<0.05). In vitro experiments indicated that downregulation of lncRNA CEBPA-AS1 could effectively reduce cell proliferation, invasion and EMT process |
| Pubmed ID | 31646559 |
| Year | 2019 |
| Title | High-expression of lncRNA CEBPA-AS1 promotes liver cancer progression |
External Links
| Links for CEBPA-AS1 | GenBank HGNC NONCODE |
| Links for liver cancer | OMIM COSMIC |